04:43 , Dec 15, 2018 |  BioCentury  |  Product Development

O’Day’s expansive task at Gilead

A fresh executive team and a track record of building deep portfolios could allow incoming Gilead Sciences Inc. chairman and CEO Daniel O’Day to do what his predecessors couldn’t: make Gilead a leader outside of...
17:56 , Aug 29, 2018 |  BC Innovations  |  Distillery Techniques

Drug platforms; imaging

TECHNOLOGY: Structural analyses; other An electron microscopy-based method for identifying epitopes that elicit potent neutralizing antibodies could be used to guide the development of vaccines for infectious diseases. The method involves six steps: digesting animal-...
21:45 , Dec 1, 2017 |  BC Week In Review  |  Clinical News

Critical Outcomes expands Phase I COTI-2 study to HNSCC

Critical Outcome Technologies Inc. (TSX-V:COT; OTCQB:COTQF) expanded an open-label, U.S. Phase I trial evaluating oral COTI-2 in gynecological malignancies to include up to 36 patients with squamous cell carcinoma of the head and neck (SCCHN)...
16:54 , May 25, 2017 |  BC Innovations  |  Translation in Brief

Neutralizing neutrophils

Scientists at the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) uncovered a new role for a known kinase in neutrophil activation and blocked the protein to treat inflammatory diseases. Pathway data suggest targeting the kinase...
14:06 , May 16, 2017 |  BC Innovations  |  Distillery Therapeutics

Autoimmune disease; gastrointestinal

INDICATION: Arthritis; psoriasis; colitis Patient sample and mouse studies suggest inhibiting MAP3K8 could help treat arthritis, psoriasis and colitis. In inflamed colon tissue or skin lesion samples from Crohn's disease or psoriasis patients, respectively, levels...
20:02 , Apr 21, 2017 |  BC Extra  |  Clinical News

Study links MAP3K8 to inflammatory diseases

In a paper published in Science Signaling , researchers from the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) characterized the role of the mitogen-activated protein kinase kinase kinase 8 ( MAP3K8 ; COT; TPL2) pathway...
07:00 , Jun 13, 2016 |  BC Week In Review  |  Financial News

Critical Outcome Technologies completes warrant exercise

Critical Outcome Technologies Inc. (TSX-V:COT; OTCQB:COTQF), London, Ontario   Business: Cancer, Autoimmune, Infectious   Date completed: 2016-06-03   Type: Warrant exercise   Raised: C$1.6 million ($1.3 million)   Shares: 5.8 million   Shares after offering:...
08:00 , Feb 22, 2016 |  BC Week In Review  |  Clinical News

COTI-2: Phase I started

Critical Outcome began an open-label, U.S. Phase I trial to evaluate oral COTI-2 in up to 46 patients with platinum-resistant, recurrent ovarian, endometrial or cervical cancer. Patients will receive COTI-2 for 5 consecutive days followed...
07:00 , Aug 10, 2015 |  BC Week In Review  |  Financial News

Critical Outcome Technologies completes private placement of units

Critical Outcome Technologies Inc. (TSX-V:COT; OTCQB:COTQF), London, Ontario   Business: Cancer, Autoimmune, Infectious   Date completed: 2015-08-04   Type: Private placement of units   Raised: C$836,560 ($636,622)   Units: 2.8 million   Price: C$0.30 (unit)...
08:00 , Feb 23, 2015 |  BC Week In Review  |  Financial News

Critical Outcome Technologies Inc completes private placement of units

Critical Outcome Technologies Inc . (TSX-V:COT; OTCQB:COTQF), London, Ontario   Business: Cancer, Autoimmune, Infectious   Date completed: 2015-02-18   Type: Private placement of units   Raised: C$542,990 ($436,510)   Units: 2.1 million   Price: C$0.26...